EXCLUSIVE: Telomir Pharmaceuticals Reports Potential Of Telomir-1 For Wilson's Disease
EXCLUSIVE: Telomir Pharmaceuticals Reports Potential Of Telomir-1 For Wilson's Disease
Offering a safer alternative to current treatments, which have significant side effects and require lifelong adherence, Telomir-1 targets the disease's root cause and may qualify for orphan drug designation.On Monday, Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) announced preclinical findings highlighting the copper-binding potential of its lead compound, Telomir-1, as a promising treatment for Wilson's disease and related disorders. The compound exhibits a binding affinity for copper ions, enabling precise regulation of copper metabolism and interacting with essential ions such as copper, iron, and zinc, the company said.
在週一，Telomir製藥公司（納斯達克：TELO）宣佈了前臨牀研究結果，強調其主要化合物Telomir-1對銅的結合潛力，作爲治療威爾遜病及相關疾病的有前景的治療方案。該化合物對銅離子表現出結合親和力，能夠精確調節銅的代謝，並與銅、鐵和鋅等必需離子相互作用，公司表示。
Recent preclinical studies by Recipharm and Smart Assays reveal Telomir-1's strong copper-binding affinity, enabling precise regulation of copper metabolism and interaction with essential ions.
最近，Recipharm和Smart Assays的前臨牀研究揭示了Telomir-1強大的銅結合親和力，使得能夠精確調節銅的代謝並與必需離子相互作用。
According to the company, these findings position Telomir-1 as a potential breakthrough therapy for Wilson's disease, a rare disorder caused by ATP7B mutations leading to toxic copper buildup in vital organs.
根據公司說法，這些發現使Telomir-1成爲威爾遜病的潛在突破性療法，威爾遜病是一種由ATP70億突變引起的罕見疾病，會導致重要器官中有毒銅的積聚。
Offering a safer alternative to current treatments, which have significant side effects and require lifelong adherence, Telomir-1 targets the disease's root cause and may qualify for orphan drug designation.
Telomir-1提供了一種比當前治療方案更安全的替代選擇，後者有顯著的副作用並需要終身堅持，Telomir-1針對疾病的根本原因，並可能獲得孤兒藥資格。
Telomir is also advancing Telomir-1's therapeutic potential in related areas, including Type 2 diabetes and age-related diseases.
Telomir還正在推進Telomir-1在相關領域的治療潛力，包括2型糖尿病和與年齡相關的疾病。
The company is optimizing GMP-grade production for IND-enabling studies scheduled for second quarter of 2025, with an IND submission planned for the fourth quarter and first-in-human clinical trials expected by mid-2026. Efforts also include securing an INAD for pets and exploring Telomir-1's dual applications in human and veterinary medicine.
公司正在優化GMP級別的生產，以便於2025年第二季度進行IND啓動研究，計劃在第四季度提交IND，並預計在2026年中期進行首次人類臨牀試驗。努力還包括爲寵物確保INAD，並探索Telomir-1在人類和獸醫學中的雙重應用。
In line with its ethical practices, Telomir discontinued its osteoarthritis study in dogs after the safety phase due to concerns over inducing the condition. The company is now collaborating with a veterinary institution to design a study using elderly dogs naturally affected by osteoarthritis, advancing its INAD application for pets.
根據其道德實踐，Telomir在安全階段後停用了對犬類的骨關節炎研究，因爲擔心誘發該控制項。公司現在正與一家獸醫機構合作設計一項研究，利用自然受骨關節炎影響的老年狗，推進其寵物的INAD申請。
"As we look to 2025, Telomir remains dedicated to its mission," said Erez Aminov, Chairman and CEO. "We are pleased to have secured additional financing at a 20% premium with no warrants, providing the resources needed to continue advancing Telomir-1's development while creating value for our shareholders."
「展望2025年，Telomir依然致力於其使命，」董事長兼首席執行官Erez Aminov說。「我們很高興以20%的溢價獲得了額外融資且無Warrants，這爲繼續推進Telomir-1的發展提供了所需資源，同時爲我們的股東創造價值。」
Price Action: TELO shares closed 14.10% higher at $5.18 on Friday.
價格走勢：TELO股票在週五收盤上漲14.10%，達$5.18。
譯文內容由第三人軟體翻譯。
